Alios BioPharma Garners $41,000,000 Series B Funding Round

  • Feed Type
  • Date
  • Company Name
    Alios BioPharma
  • Mailing Address
    260 East Grand Ave 2nd Floor South San Francisco, CA 94080 USA
  • Company Description
    Alios is discovering and developing novel therapeutic agents based on three platform technologies including: small molecule activators of innate immunity antiviral pathways (RNase L activation), phosphate protected nucleotide prodrug chemistry, and glycoprotein-engineering of interferons (Glycoferonâ).
  • Website
  • Transaction Type
    Venture Equity
  • Transaction Amount
  • Transaction Round
    Series B
  • Proceeds Purposes
    Proceeds from this financing will be used primarily to support continued clinical development of Alios’ respiratory portfolio, including AL-8176, an anti-RSV nucleoside analog now in Phase 2 clinical development, and multiple late-stage preclinical development programs targeting Influenza and Rhinovirus.
  • M&A Terms
  • Venture Investor
  • Venture Investor
  • Venture Investor
  • Venture Investor
  • Venture Investor

Trending on Xconomy